[Olaparib in ovarian cancer with BRCA mutation]

Bull Cancer. 2015 Jun;102(6 Suppl 1):S82-4. doi: 10.1016/S0007-4551(15)31221-2.
[Article in French]

Abstract

With 4500 new cases and 3200 death each year, ovarian cancer is the first cause of mortality for gynecological cancer in France. Without any efficient screening, it is usually diagnosed around the age of 60 years at an advanced stage. The emergence of olaparib, a new targeted therapy, represents a major opportunity.

Keywords: BRCA; Cancer de l'ovaire; Olaparib; Ovarian cancer; PARP.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Female
  • Gene Silencing
  • Genes, BRCA1*
  • Genes, BRCA2
  • Humans
  • Middle Aged
  • Mutation
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / prevention & control
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / pathology
  • Phthalazines / therapeutic use*
  • Piperazines / therapeutic use*
  • Poly(ADP-ribose) Polymerase Inhibitors*

Substances

  • Antineoplastic Agents
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • olaparib